Hohimer Wealth Management LLC Has $539,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Hohimer Wealth Management LLC decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,075 shares of the medical research company’s stock after selling 365 shares during the period. Hohimer Wealth Management LLC’s holdings in Edwards Lifesciences were worth $539,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Nordea Investment Management AB lifted its position in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares during the period. Telos Capital Management Inc. boosted its stake in Edwards Lifesciences by 158.2% during the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after buying an additional 56,000 shares in the last quarter. Arlington Trust Co LLC increased its holdings in Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after buying an additional 12,069 shares during the period. Versor Investments LP raised its stake in shares of Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after buying an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $1,587,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.7 %

Shares of NYSE:EW traded up $0.59 during trading on Friday, hitting $88.05. 641,455 shares of the company’s stock were exchanged, compared to its average volume of 3,539,494. The firm has a 50-day moving average price of $89.77 and a two-hundred day moving average price of $81.38. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a market cap of $53.06 billion, a P/E ratio of 37.88, a PEG ratio of 3.30 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Barclays upped their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Finally, Mizuho boosted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.31.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 180,707 shares of company stock worth $16,034,814. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.